Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- September30 2003
- Volume 10
- Issue 18
After You're Gone
Author(s)Michael Sheehan
Advertisement
You may have your estate plans ingood shape, but if you don't let familymembers in on the details, they will haveto figure out your wishes after you die.That's a situation that could easily leadto confusion and even family discord.A list that includes bank and brokeraccount numbers, insurance policyinformation, and computer passwordsto access online financial data is essential.You should also include informationon where to find important documentslike your will and powers ofattorney. Your Family Records Organizer,a CD available from Kiplinger's(800-280-7165; www.kiplinger.com/organizer), can help you getorganized with all your importantestate data in 1 place.
Articles in this issue
about 18 years ago
Distinguish Tax Loopholes and Tax Scamsabout 18 years ago
Reduce Your Retirement Plan's Tax Biteabout 18 years ago
Do You Hold an Adequate Disability Plan?about 18 years ago
Research the Facts Before You Refinanceabout 18 years ago
Lend Your Parents a Safe Financial Handabout 18 years ago
Learn to Diagnose and Treat a Sick Homeabout 18 years ago
Remember: Money Isn't Who You Areabout 18 years ago
Get Back to Basic Barteringabout 18 years ago
Know the Duties of an Estate Executorabout 18 years ago
Portfolio CHECK-UPAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5